Amneal Pharmaceuticals (NASDAQ:AMRX) reported better-than-expected second-quarter results on Tuesday, as strength in its Specialty division helped lift earnings, prompting the company to raise its full-year profit guidance.
Adjusted earnings for the quarter came in at $0.25 per share, beating the $0.17 analyst consensus and marking a 56% jump from $0.16 in the same quarter last year. Revenue grew 3% year-over-year to $725 million, just shy of the $748.18 million analysts had forecast.
The standout performer was the Specialty segment, where revenue climbed 23%, bolstered by robust sales of key branded therapies such as CREXONT, RYTARY, and UNITHROID. The Affordable Medicines unit recorded a 1% increase, while AvKARE saw a 4% decline.
“Amneal delivered another quarter of solid growth, strong profitability, and we are pleased to raise our full year 2025 guidance,” said Chirag and Chintu Patel, Co-Chief Executive Officers. “The quarter was also marked by strong commercial uptake of CREXONT for Parkinson’s disease, and the FDA approval of Brekiya autoinjector for the acute treatment of migraine and cluster headache in adults.”
Adjusted EBITDA rose 13% year-on-year to $184 million, driven by increased revenue and improved gross margins.
Reflecting the strong results, Amneal revised its full-year 2025 earnings forecast upward to $0.70–$0.75 per share, compared to the previous range of $0.65–$0.70. The updated guidance is in line with the $0.71 consensus. The company maintained its revenue forecast at $3.0–$3.1 billion.
Additionally, Amneal completed a $2.7 billion debt refinancing on August 1. The company said the move will lower its interest expenses and extend debt maturities to 2032, enhancing its financial flexibility.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.